ID

12959

Beschreibung

Trastuzumab and Erlotinib as First-Line Therapy in Treating Women With Metastatic Breast Cancer Associated With HER2/Neu Overexpression; ODM derived from: https://clinicaltrials.gov/show/NCT00033514

Link

https://clinicaltrials.gov/show/NCT00033514

Stichworte

  1. 07.01.16 07.01.16 -
Hochgeladen am

7. Januar 2016

DOI

Für eine Beantragung loggen Sie sich ein.

Lizenz

Creative Commons BY 4.0

Modell Kommentare :

Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.

Itemgroup Kommentare für :

Item Kommentare für :

Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.

Eligibility Breast Cancer NCT00033514

Eligibility Breast Cancer NCT00033514

Inclusion Criteria
Beschreibung

Inclusion Criteria

Alias
UMLS CUI
C1512693
women aged > 18 years
Beschreibung

age, gender

Datentyp

boolean

Alias
UMLS CUI [1]
C0001779
UMLS CUI [2]
C0079399
histologically documents metastatic breast cancer
Beschreibung

histology metastasis

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0019638
UMLS CUI [1,2]
C0027627
her2 positive using fish
Beschreibung

FISH her2 positive

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0162789
UMLS CUI [1,2]
C0242957
for phase i, patients who have previously received treatment for their metastatic disease are allowed to participate.
Beschreibung

previous treatment

Datentyp

boolean

Alias
UMLS CUI [1]
C0087111
for the phase ii portion of the study, patients must have measureable disease (> 2 cm; > 1 cm on spiral ct scan)
Beschreibung

measureable disease

Datentyp

boolean

Alias
UMLS CUI [1]
C0475440
UMLS CUI [2]
C0860888
ecog performance status of 0 to 2
Beschreibung

ecog performance status

Datentyp

boolean

Alias
UMLS CUI [1]
C1520224
a life expectancy of > 3 months
Beschreibung

life expectancy

Datentyp

boolean

Alias
UMLS CUI [1]
C0023671
use of effective means of contraception
Beschreibung

contraception

Datentyp

boolean

Alias
UMLS CUI [1]
C0700589
Exclusion Criteria
Beschreibung

Exclusion Criteria

Alias
UMLS CUI
C0680251
for phase ii, prior cytotoxic chemotherapy and/or prior herceptin for their metastatic disease. prior treatment in the adjuvant setting is allowed.
Beschreibung

chemotherapy, herceptin

Datentyp

boolean

Alias
UMLS CUI [1]
C0392920
UMLS CUI [2]
C0338204

Ähnliche Modelle

Eligibility Breast Cancer NCT00033514

Name
Typ
Description | Question | Decode (Coded Value)
Datentyp
Alias
Item Group
C1512693 (UMLS CUI)
age, gender
Item
women aged > 18 years
boolean
C0001779 (UMLS CUI [1])
C0079399 (UMLS CUI [2])
histology metastasis
Item
histologically documents metastatic breast cancer
boolean
C0019638 (UMLS CUI [1,1])
C0027627 (UMLS CUI [1,2])
FISH her2 positive
Item
her2 positive using fish
boolean
C0162789 (UMLS CUI [1,1])
C0242957 (UMLS CUI [1,2])
previous treatment
Item
for phase i, patients who have previously received treatment for their metastatic disease are allowed to participate.
boolean
C0087111 (UMLS CUI [1])
measureable disease
Item
for the phase ii portion of the study, patients must have measureable disease (> 2 cm; > 1 cm on spiral ct scan)
boolean
C0475440 (UMLS CUI [1])
C0860888 (UMLS CUI [2])
ecog performance status
Item
ecog performance status of 0 to 2
boolean
C1520224 (UMLS CUI [1])
life expectancy
Item
a life expectancy of > 3 months
boolean
C0023671 (UMLS CUI [1])
contraception
Item
use of effective means of contraception
boolean
C0700589 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
chemotherapy, herceptin
Item
for phase ii, prior cytotoxic chemotherapy and/or prior herceptin for their metastatic disease. prior treatment in the adjuvant setting is allowed.
boolean
C0392920 (UMLS CUI [1])
C0338204 (UMLS CUI [2])

Benutzen Sie dieses Formular für Rückmeldungen, Fragen und Verbesserungsvorschläge.

Mit * gekennzeichnete Felder sind notwendig.

Benötigen Sie Hilfe bei der Suche? Um mehr Details zu erfahren und die Suche effektiver nutzen zu können schauen Sie sich doch das entsprechende Video auf unserer Tutorial Seite an.

Zum Video